News |
News |
News |
News |
£40.8bn
Turnover [1]
15%
R and D Investment [2]
£14bn
Gross Value Added services (GVA) [4]
Clinical trials are essential for testing whether new medicines are safe and effective but it really is just the beginning of the journey.
It must be monitored and regulated for their whole lifetime.
A medicine’s licence is the green light for it to be given to patients and it covers everything about how it should be used, who it's for, and what dose is appropriate.
It then needs to pass strict tests to make sure it's cost effective for the NHS.
Once a medicine is made available, the pharmaceutical company has a duty to continue to monitor it and make sure that performs safely for as long as it's on the market.
This process is called pharmacovigilance and it helps inform regulators about previously unknown side effects, but it can also help to collect additional information, real-world data that can be fed back to improve future research.
More data means a better understanding of what medicine can do often allowing it to be used to treat even more conditions or used in completely different set of patients.
The data can be fed back to progress basic science and unlock treatments for future generations.
June has sickle cell, a genetic blood disorder that affects the red blood cells. She is one of the 1 in 17 people with a rare disease in the UK.
Gilead Sciences has joined the membership of the Association of the British Pharmaceutical Industry, effective from January 2022.
It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout. The point of using Lorem Ipsum is that it has a more-or-less normal distribution of letters, as opposed to using 'Content here, content here', making it look like readable English. Many desktop publishing packages and web page editors now use Lorem Ipsum as their default model text, and a search for
People who work for the ABPI make a difference. We are at the heart of a multi-billion pound pharmaceutical industry. Roles at the ABPI range from close liaison with Government and the NHS to working with education organisations and the media.
The ABPI exists to make the UK the best place in the world to research, develop and access medicines and vaccines to improve patient care.
In England, Scotland, Wales and Northern Ireland, we work in partnership with governments and the NHS so that patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, our members partner with healthcare professionals, academics and patient organisations to find new solutions to unmet health needs.
Clinical trials are essential for testing whether new medicines are safe and effective but it really is just the beginning of the journey.
It must be monitored and regulated for their whole lifetime.
A medicine’s licence is the green light for it to be given to patients and it covers everything about how it should be used, who it's for, and what dose is appropriate.
It then needs to pass strict tests to make sure it's cost effective for the NHS.
Once a medicine is made available, the pharmaceutical company has a duty to continue to monitor it and make sure that performs safely for as long as it's on the market.
This process is called pharmacovigilance and it helps inform regulators about previously unknown side effects, but it can also help to collect additional information, real-world data that can be fed back to improve future research.
More data means a better understanding of what medicine can do often allowing it to be used to treat even more conditions or used in completely different set of patients.
The data can be fed back to progress basic science and unlock treatments for future generations.
Medicines and vaccines are transforming our lives like never before.
We want the UK to be the best place in the world to research,
develop and use the medicines and vaccines of the future.
To do this, we focus on:
Working in partnership with Government, the NHS and the life science community
Improving Access to New Medicines and Vaccines so everyone in the UK can get the latest treatments.
Building a Thriving Environment for medicine discovery so the UK can be the best place in the world to research and develop new medicines and vaccines.
Enhancing reputation by demonstrating the high ethical standards we set ourselves and that society expects from us.
Providing UK leadership to drive global medicines policy.
Improving how health data can transform medicine development and improve patient care.
Representing our members, using their insight and experience to tell the story of how they change the lives of millions of people every day.
Partnerships between the NHS and the pharmaceutical industry benefit patients and the NHS. Visit the ABPI's library of case studies of successful partnerships.
It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout. The point of using Lorem Ipsum is that it has a more-or-less normal distribution of letters, as opposed to using 'Content here, content here', making it look like readable English. Many desktop publishing packages and web page editors now use Lorem Ipsum as their default model text, and a search for
ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum
It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout. The point of using Lorem Ipsum is that it has a more-or-less normal distribution of letters, as opposed to using 'Content here, content here', making it look like readable English. Many desktop publishing packages and web page editors now use Lorem Ipsum as their default model text, and a search for
£26.1bn
Export Value [3]
£30.8bn
Import Value [3]
66,000
People employed by the pharmaceutical sector in 2021 [1]
1,100
Life sciences apprenticeships started in 20/21 [4]
£7.3bn
Total Voluntary Scheme payments to the NHS after 5 years [5]
140
Phase III UK industry clinical trials started in 2021 [6]
Want to find out what it’s like to work in the industry? Looking for opportunities to get into the industry, or the options available to you? Trying to advise someone interested in entering the industry? This section is here to help.
Want to find out what it’s like to work in the industry? Looking for opportunities to get into the industry, or the options available to you? Trying to advise someone interested in entering the industry? This section is here to help.
Want to find out what it’s like to work in the industry? Looking for opportunities to get into the industry,
Want to find out what it’s like to work in the industry? Looking for opportunities to get into the industry,
Want to find out what it’s like to work in the industry? Looking for opportunities to get into the industry,
Want to find out what it’s like to work in the industry? Looking for opportunities to get into the industry,
Current maritime industry trends see a continued growth in the use of digital data, higher levels of integration of navigation equipment and increased use of ship-to-shore connectivity, and this results in the potential emergence of new cyber threats. The carriage of ECDIS, use of Integrated Navigation Systems
adoption of eNavigation all require an increased emphasis on cyber risk management in order to maintain safe operation of vessels at sea.
The Northrop Grumman Sperry Marine NAVIGUIDE 4000 Manual Ship Steering System is the first steering system to use ship steering control network technology. The NAVIGUIDE 4000 Manual Steering System has multiple configurations to meet specific customer requirements and is fully type approved by classification society Germanischer Lloyd.
NHS Industry Case Studies Library
Medicines and vaccines are transforming our lives like never before.
We want the UK to be the best place in the world to research,
develop and use the medicines and vaccines of the future.
